BCRX  Biocryst Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

600.26M

Vuru Grade

31.00/100

Current Price

$8.30
+0.19 (+2.34%)

Stability Price

$0.22
Overvalued by 97.38%

Company Metrics

  • 0 P/E
  • 43.10 P/S
  • 7.72 P/B
  • -0.68 EPS
  • -229.93% Cash ROIC
  • 1.26 Cash Ratio
  • 0 / N/A % Dividend
  • 861,045.00 Avg. Vol.
  • 72.32M Shares
  • 600.26M Market Cap.

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Review on Stocks On The Dive - BioCryst Pharmaceuticals, Inc. (NASDAQ ...
wsnewspublishers - Mar 24, 2015
On Monday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals VP Sells $122986.80 in Stock (BCRX) - sleekmoney
Yarlagadda S. Babu Sells 12105 Shares of BioCryst Pharmaceuticals Stock ... - WKRB News
Earnings Peek: BioCryst Pharmaceuticals Likely To Beat Estimates (BCRX)
Seeking Alpha (registration) - Jan 27, 2015
BioCryst Pharmaceuticals (NASDAQ:BCRX) is a small biotechnology company with a market cap of $814 million. It develops novel small molecule drugs that block key enzymes involved in orphan and infectious diseases.
BioCryst Pharma (BCRX) Granted Orphan Drug and Fast Track Status from the ... - Wall Street Pit
FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary ... - MarketWatch
BioCryst Pharmaceuticals, Inc. Insider Transaction Update: Yarlagadda Babu ...
Stafford Daily - Mar 9, 2015
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX),The Officer (Senior VP - Drug Discovery) of BioCryst Pharmaceuticals, Inc., Babu Yarlagadda S sold 37,400 shares at $10.59 on March 5, 2015. The Insider selling transaction had a total value worth of ...
Insider Selling: BioCryst Pharmaceuticals VP Yarlagadda S. Babu Sells 37400 ... - Dakota Financial News
Company Shares of BioCryst Pharmaceuticals, Inc. Drops by -1.52% - Winston View
Technical Insights on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
Markets Wired - Mar 5, 2015
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the following investor ...
Insider Selling: BioCryst Pharmaceuticals VP Sells 10495 Shares of Stock (BCRX) - sleekmoney
Insider Selling: BioCryst Pharmaceuticals VP Yarlagadda S. Babu Sells 10495 ... - Mideast Time
Downward Momentum Stocks: BioCryst Pharmaceuticals, (NASDAQ:BCRX ...
wsnewspublishers - Mar 25, 2015
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) decreased -2.66%, and closed at $8.78. The company holds the market capitalization of $652.33M.
Why BioCryst Pharmaceuticals Inc. Shares Soared
Motley Fool - May 27, 2014
What: Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX ) , a biotechnology company focused on developing small-molecule drugs designed to block enzymes which are vital to the disease development process, spiked higher by as much as 22% after ...
BioCryst Pharmaceuticals Prices Public Offering of Common Stock - GlobeNewswire (press release)
BioCryst Announces Positive Results From OPuS-1, a Phase 2 Trial of BCX4161 ... - MarketWatch
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) in Spotlight
Markets Wired - Feb 25, 2015
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced financial results for the fourth quarter and full year ended December 31, 2014.
Revenue Update on BioCryst Pharmaceuticals, Inc. - Ashburn Daily
Insider Buying: Nancy J. Hutson Buys 10000 Shares of BioCryst ... - Dakota Financial News
Stock in Focus: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
Markets Wired - Jan 12, 2015
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's development programs at ...
Analyst Rating Update on BioCryst Pharmaceuticals, Inc.
Bar and Graph Report - Mar 13, 2015
Analysts at Zacks have given a short term rating of hold on Biocryst Pharmaceuticals (NASDAQ:BCRX) with a rank of 3. The counter has received an average rating of 1.71 from 7 brokerage firms.
BioCryst Pharmaceuticals Short Interest Up 15.8% in February (BCRX) - WKRB News
Can BioCryst Pharmaceuticals, Inc. (BCRX) Stop The Ebola Outbreak?
ETF Daily News - Aug 5, 2014
Currently there are no approved vaccines or drugs to treat Ebola. All doctors can do is give patients fluid and try to stop the bleeding that Ebola causes.
BioCryst Pharmaceuticals' (BCRX) CEO Jon Stonehouse on Q2 2014 Results ... - Seeking Alpha (registration)
BioCryst Pharmaceuticals (BCRX) Continues to Rise on Potential Ebola Treatment - Equities.com